Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
125 hedge funds and large institutions have $912M invested in Verve Therapeutics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 34 reducing their positions, and 19 closing their positions.
307% more call options, than puts
Call options by funds: $1.98M | Put options by funds: $485K
24% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 34
11% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 19
2% more funds holding
Funds holding: 123 → 125 (+2)
0.67% more ownership
Funds ownership: 101.68% → 102.34% (+0.67%)
25% less capital invested
Capital invested by funds: $1.21B → $912M (-$300M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.6M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$7.24M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$7.24M |
| 4 |
Citigroup
New York
|
+$6.43M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$6.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$22M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$13.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.8M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$4.18M |
| 5 |
CC
Casdin Capital
New York
|
-$3.33M |
VERV Hedge Fund Activity: Q1 2023 in Review
125 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q1 2023, worth a combined $912M — down 25% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new VERV positions and 19 closed out — a net gain of 2 holders — while 42 added to existing stakes and 34 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $7.6M. The largest seller was State Street, cutting an estimated $22M.
- 125 institutional investors held Verve Therapeutics (VERV) as of Q1 2023, up from 123 in Q4 2022.
- Funds reported $912M of Verve Therapeutics stock for Q1 2023, down 25% quarter-over-quarter.
- 21 funds opened new Verve Therapeutics positions in Q1 2023 and 19 closed out, a net change of +2 holders.
- The largest Verve Therapeutics buyer in Q1 2023 was Citadel Advisors, an estimated $7.6M added.
- The largest Verve Therapeutics seller in Q1 2023 was State Street, an estimated $22M sold.
Based on aggregated 13F filings for Q1 2023.